×
S&P 500   3,820.84 (+0.94%)
DOW   31,064.50 (+0.94%)
QQQ   282.25 (+0.70%)
AAPL   138.68 (+1.43%)
MSFT   259.68 (+1.11%)
META   159.87 (-0.86%)
GOOGL   2,174.54 (-0.22%)
AMZN   109.61 (+3.20%)
TSLA   679.75 (+0.94%)
NVDA   145.26 (-4.18%)
NIO   21.40 (-1.47%)
BABA   116.08 (+2.11%)
AMD   73.75 (-3.56%)
MU   53.62 (-3.00%)
CGC   2.82 (-1.05%)
T   21.36 (+1.91%)
GE   63.81 (+0.22%)
F   11.31 (+1.62%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   71.46 (+2.32%)
NFLX   179.97 (+2.92%)
S&P 500   3,820.84 (+0.94%)
DOW   31,064.50 (+0.94%)
QQQ   282.25 (+0.70%)
AAPL   138.68 (+1.43%)
MSFT   259.68 (+1.11%)
META   159.87 (-0.86%)
GOOGL   2,174.54 (-0.22%)
AMZN   109.61 (+3.20%)
TSLA   679.75 (+0.94%)
NVDA   145.26 (-4.18%)
NIO   21.40 (-1.47%)
BABA   116.08 (+2.11%)
AMD   73.75 (-3.56%)
MU   53.62 (-3.00%)
CGC   2.82 (-1.05%)
T   21.36 (+1.91%)
GE   63.81 (+0.22%)
F   11.31 (+1.62%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   71.46 (+2.32%)
NFLX   179.97 (+2.92%)
S&P 500   3,820.84 (+0.94%)
DOW   31,064.50 (+0.94%)
QQQ   282.25 (+0.70%)
AAPL   138.68 (+1.43%)
MSFT   259.68 (+1.11%)
META   159.87 (-0.86%)
GOOGL   2,174.54 (-0.22%)
AMZN   109.61 (+3.20%)
TSLA   679.75 (+0.94%)
NVDA   145.26 (-4.18%)
NIO   21.40 (-1.47%)
BABA   116.08 (+2.11%)
AMD   73.75 (-3.56%)
MU   53.62 (-3.00%)
CGC   2.82 (-1.05%)
T   21.36 (+1.91%)
GE   63.81 (+0.22%)
F   11.31 (+1.62%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   71.46 (+2.32%)
NFLX   179.97 (+2.92%)
S&P 500   3,820.84 (+0.94%)
DOW   31,064.50 (+0.94%)
QQQ   282.25 (+0.70%)
AAPL   138.68 (+1.43%)
MSFT   259.68 (+1.11%)
META   159.87 (-0.86%)
GOOGL   2,174.54 (-0.22%)
AMZN   109.61 (+3.20%)
TSLA   679.75 (+0.94%)
NVDA   145.26 (-4.18%)
NIO   21.40 (-1.47%)
BABA   116.08 (+2.11%)
AMD   73.75 (-3.56%)
MU   53.62 (-3.00%)
CGC   2.82 (-1.05%)
T   21.36 (+1.91%)
GE   63.81 (+0.22%)
F   11.31 (+1.62%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   71.46 (+2.32%)
NFLX   179.97 (+2.92%)
NASDAQ:BFRI

Biofrontera Stock Forecast, Price & News

$1.78
-0.08 (-4.30%)
(As of 07/1/2022 03:27 PM ET)
Add
Compare
Today's Range
$1.78
$1.91
50-Day Range
$1.86
$4.06
52-Week Range
$1.80
$14.63
Volume
7,612 shs
Average Volume
2.00 million shs
Market Capitalization
$33.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
30 days | 90 days | 365 days | Advanced Chart

Receive BFRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

BFRI Stock Forecast (MarketRank)

Overall MarketRank

1.38 out of 5 stars

Medical Sector

1111th out of 1,429 stocks

Pharmaceutical Preparations Industry

549th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Biofrontera logo

About Biofrontera (NASDAQ:BFRI)

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

BFRI Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BFRI
Fax
N/A
Employees
69
Year Founded
N/A

Company Calendar

Last Earnings
4/08/2022
Today
7/01/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+770.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$24.10 million
Book Value
$0.66 per share

Miscellaneous

Free Float
N/A
Market Cap
$33.74 million
Optionable
Not Optionable
Beta
N/A














Biofrontera Frequently Asked Questions

Should I buy or sell Biofrontera stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Biofrontera stock.
View analyst ratings for Biofrontera
or view top-rated stocks.

What is Biofrontera's stock price forecast for 2022?

2 Wall Street research analysts have issued 12 month target prices for Biofrontera's shares. Their BFRI stock forecasts range from $11.00 to $20.00. On average, they predict Biofrontera's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 770.8% from the stock's current price.
View analysts' price targets for Biofrontera
or view top-rated stocks among Wall Street analysts.

How has Biofrontera's stock performed in 2022?

Biofrontera's stock was trading at $7.52 at the beginning of 2022. Since then, BFRI stock has decreased by 76.3% and is now trading at $1.78.
View the best growth stocks for 2022 here
.

When is Biofrontera's next earnings date?

Biofrontera is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Biofrontera
.

How were Biofrontera's earnings last quarter?

Biofrontera Inc. (NASDAQ:BFRI) posted its quarterly earnings data on Friday, April, 8th. The company reported ($0.42) earnings per share (EPS) for the quarter. The business had revenue of $9.17 million for the quarter.
View Biofrontera's earnings history
.

What guidance has Biofrontera issued on next quarter's earnings?

Biofrontera issued an update on its FY 2022 earnings guidance on Friday, June, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $31.33M-, compared to the consensus revenue estimate of $40.70 million.

Who are Biofrontera's key executives?

Biofrontera's management team includes the following people:
  • Dr. Hermann Lubbert Ph.D., Exec. Chairman & Pres (Age 66, Pay $18.02k)
  • Ms. Erica L. Monaco CPA, CEO, CFO, COO, Treasurer & Sec. (Age 37, Pay $402.12k)
  • Ms. Erica F. Gates CPA, M.B.A., Sr. Director of Fin. & Principal Accounting Officer
  • Mr. Daniel Hakansson J.D., Gen. Counsel & Head of Compliance
  • Mr. Mark Baldyga, Head of Sales & Marketing
  • Mr. Jeff Holm, Head of Professional Relations & Commercial Devel.

When did Biofrontera IPO?

(BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO.

What is Biofrontera's stock symbol?

Biofrontera trades on the NASDAQ under the ticker symbol "BFRI."

How do I buy shares of Biofrontera?

Shares of BFRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biofrontera's stock price today?

One share of BFRI stock can currently be purchased for approximately $1.78.

How much money does Biofrontera make?

Biofrontera (NASDAQ:BFRI) has a market capitalization of $33.74 million and generates $24.10 million in revenue each year.

How many employees does Biofrontera have?

Biofrontera employs 69 workers across the globe.

How can I contact Biofrontera?

The official website for Biofrontera is www.biofrontera-us.com. The company can be reached via phone at 781-245-1325 or via email at [email protected].

This page (NASDAQ:BFRI) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.